Economic evaluation of human papillomavirus vaccination in the United Kingdom (Q36818045)

16 August 2017

Economic evaluation of human papillomavirus vaccination in the United Kingdom (English)

1 reference

16 August 2017

1

Mark Jit

1 reference

16 August 2017

3

W John Edmunds

1 reference

16 August 2017

Yoon Hong Choi

2

1 reference

PMC publication ID

2500202

16 August 2017

language of work or name

English

0 references

publication date

17 July 2008

1 reference

16 August 2017

1 reference

16 August 2017

337

1 reference

16 August 2017

a769

1 reference

Financing Vaccines in the 21st Century: Assuring Access and Availability

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Cost-effectiveness of human papillomavirus vaccination in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Prevalence of human papillomavirus antibodies in young female subjects in England

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Model for assessing human papillomavirus vaccination strategies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

The global health burden of infection-associated cancers in the year 2002

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

The costs of treating external genital warts in England and Wales: a treatment pattern analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

The cervical cancer epidemic that screening has prevented in the UK.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

A catalog of dermatology utilities: a measure of the burden of skin diseases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Epidemiologic classification of human papillomavirus types associated with cervical cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Estimation of the impact of genital warts on health-related quality of life.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

Trends in cervical cancer survival in Europe, 1983–1994: A population-based study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500202

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

4 December 2018

1 reference

12 December 2020

Costs of running a universal adolescent hepatitis B vaccination programme

1 reference

12 December 2020

Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites

1 reference

12 December 2020

Papillomavirus vaccines in perspective

1 reference

12 December 2020

Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales

1 reference

12 December 2020

Stage-specific treatment costs for cervical cancer in the United Kingdom

1 reference

12 December 2020

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

1 reference

12 December 2020

European guideline for the management of anogenital warts

1 reference

12 December 2020

Abnormal outcomes following cervical cancer screening: event duration and health utility loss

1 reference

12 December 2020

Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996

1 reference

12 December 2020

Identifiers

DOI

10.1136/BMJ.A769

1 reference

16 August 2017

1 reference

PMC publication ID

2500202

16 August 2017

PubMed publication ID

18640957

1 reference

PMC publication ID

2500202